BROWN MICHAEL S 4
4 · REGENERON PHARMACEUTICALS, INC. · Filed Feb 8, 2023
Insider Transaction Report
Form 4
BROWN MICHAEL S
Director
Transactions
- Sale
Common Stock
2023-02-06$798.00/sh−3,071$2,450,658→ 1,247 total - Exercise/Conversion
Common Stock
2023-02-06$520.01/sh+3,071$1,596,951→ 4,318 total - Exercise/Conversion
Non-Qualified Stock Option (right to buy)
2023-02-06−3,071→ 3,070 totalExercise: $520.01Exp: 2026-01-04→ Common Stock (3,071 underlying) - Sale
Common Stock
2023-02-06$797.00/sh−500$398,500→ 6,162 total(indirect: By Trust)
Holdings
- 5,000(indirect: by SLAT)
Common Stock
Footnotes (3)
- [F1]Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).
- [F2]These shares are held in a trust for the benefit of the reporting person's immediate family members. The reporting person's spouse is trustee of the trust. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
- [F3]The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant.